This patient had done everything right. Six months earlier, he had come into my office barely able to lift his arm above shoulder height, the result of a rotator cuff injury that had quietly worsened over a year of ignoring it. We treated it with the art of clinical approach: an image-guided intra-articular injection to calm the inflammation, followed by a disciplined course of physical therapy. He showed up for therapy diligently, week after week, without excuses or complaints. This is not the case with every patient. By his six-month follow-up, his range of motion had pretty much returned. His pain was gone. By every clinical measure, he was a success story. He sat on the exam table, moved his arm through a full pain-free arc of motion, and then looked down at himself with something between disappointment and hesitation. He admitted that his shoulder worked fine now, mostly, but he did not feel like a man whose shoulder worked fine. The muscle around his shoulder had thinned during the months he had favored the joint, and at sixty-two, it was not returning to the state it was in when he was forty.
Then he asked me the question I now hear almost weekly. He had read that a peptide called BPC-157 could potentially rebuild what the injury and the inactivity had cost him. He wondered if he should try it. He didn’t know much about this treatment other than the auspicious claims surrounding it. I could understand exactly why he asked. We are living longer than any generation in human history, and more importantly, we are living better longer. “health span,” not merely lifespan, has become a guiding idea for modern medicine. The pursuit of life added to years, rather than years added to life. That shift in perspective is real, measurable, and, in my opinion, one of the genuine triumphs of my profession.
But sitting across from a man who had just done the hard, unglamorous work of healing correctly, only to wonder whether a vial from the internet could finish the job faster or better, made me feel the full weight of how far the conversation has drifted from the standards of evidence-based medicine. Peptides are not new to medicine. Insulin is a peptide. So is semaglutide. Used within a regulated, well-studied framework, peptide therapeutics have improved the practice of medicine. That legitimate history is what the current market for hyped-up medications is leveraging so persuasively. It borrows the credibility of real pharmacology and lends it to substances that have not yet earned it. BPC-157 itself is a synthetic peptide derived from a protein found in human gastric juice, and in animal models it shows genuine promise for tissue repair, gut healing, and modulation of the nitric oxide and angiogenesis pathways involved in recovery.
But the human pharmacokinetic data remain thin, and the plasma half-life measured in animal studies is under 30 minutes. Researchers who study this molecule openly acknowledge that almost every trial uses a single dose, which means we simply do not know what repeated, escalating, self-administered dosing does to a human body over months or years. There are no studies documenting long-term efficacy or safety. Even short-term efficacy results are not supported by controlled human clinical studies. Dosing remains to be fully characterized.
Real physician voices, twice a week
Join 100,000+ subscribers. Free, and one click to unsubscribe.
This past summer, an FDA advisory committee voted narrowly, over the objections of the agency’s own scientists, to recommend BPC-157 and several related peptides for possible inclusion on the list of substances compounding pharmacies may legally prepare. Even on an optimistic timeline, that process is at least a year or two from producing anything available at a licensed pharmacy counter. Meanwhile, millions of Americans are already using these compounds through unregulated channels, some of which have been found to contain contaminants, heavy metals, or a fraction of the labeled dose. We are effectively running the human trial on ourselves, generating anecdotal data outside any institution built to manage results and monitor adverse reactions.
I told my patient none of this so that he wouldn’t dismiss my recommendations based on a presumed suspicion that I was negatively predisposed to these new alternatives. But I shared that currently there is a gap between preclinical promise and clinical certainty. This is always the case with new therapies that show promise in preclinical assessments. Hope tends to outrun wisdom and established evaluation processes meant to ensure safety and document the effectiveness of a therapy. He would be the one assuming most of the risk, not the company selling him the vial. I explained the wisdom and need for a risk-benefit understanding in starting any therapeutic regimen.
What troubles me most about that conversation was not the specific molecule he asked about. It was the assumption underlying the question that his flabby muscle was a problem to be solved with a chemical intervention rather than a signal to be addressed through physical therapy and managed recovery. His body was not broken. It was accurately reporting six months of reduced use. Muscle, bone, cognition, even the intricate machinery of hormonal signaling: All of it is maintained or allowed to senesce according to demand. Our bodies evolved under conditions of real scarcity, where sustaining unused capacity was a luxury nature could not afford. A peptide can nudge a signaling pathway. It cannot substitute for the months of resistance training that will teach his shoulder and the muscle around it that they are needed again. Expecting muscular restitution through biochemical manipulation is a poor substitute for sustained effort. Sustained effort grants adaptations to demand, and no molecule, however elegantly designed, is likely to modify a chronic condition of human physiology.
I am not saying that this peptide and others like it should never be used. They should be studied and characterized in controlled evaluations that can fully inform a risk-benefit decision. Hyping peptides as a fountain of youth risks de-emphasizing other established therapeutic alternatives, and with limited oversight, there is a risk of contamination or unknown long-term effects. As I mentioned earlier, there are many cases in which peptide candidates have proven highly effective across various therapeutic scenarios, but only after careful studies that established tolerability, correct dosing, long-term side effects, and potential interactions with other drugs. Poorly regulated manufacturing origins can lead to serious contamination situations or misrepresentation of active ingredients. That is why the drug supply of FDA-approved drugs with compliance oversight is one of the safest in the world and the drugs themselves are reliable in their effectiveness.
When the focus is on an unproven medication to correct muscular damage, we are not addressing the underlying etiology of the condition we are treating. That focus fundamentally discards the proven path to reverse this type of damage, namely, the unglamorous effort required to re-educate the body in the muscular efficiency needed for the patient’s activity and mobility expectations. This approach has the advantage of years of experience and a proven track record. This does not negate innovative approaches to the development of new medications. But the initial excitement of early results without the required rigor of clinical evaluations has led to many examples of dashed hopes and, worse, adverse medical outcomes.
My patient’s shoulder healed because he did the work the healing process required. What he was asking me, without quite realizing it, was whether he could skip that same work for the muscles around it. I told him no such shortcut exists yet, and that the science behind the one he was considering is nowhere near settled enough for it to be recommended or to justify a change in therapeutic direction. What I recommended instead was the same prescription that had already proved successful for his shoulder: Load the tissue, be patient with the timeline, and trust that the body would respond to demand the way it always has. Our grandparents were not wrong in reminding us that the body changes with age. They were often wrong, however, about how much of that change was immutable rather than alterable. We have the science, the calories, and the time to remain vital deep into our eighties. What we often miss is the discipline to believe in the body’s incredible potential for self-healing, if only we allow the time and discipline to help it fulfill its design.
This essay is for informational purposes only and does not constitute medical advice. The patient case described has been de-identified and modified to protect confidentiality. Peptide therapies discussed are not FDA-approved for the uses described and carry unknown long-term risks. Consult a licensed physician before use.
Francisco M. Torres is an interventional physiatrist specializing in diagnosing and treating patients with spine-related pain syndromes. He is certified by the American Board of Physical Medicine and Rehabilitation and the American Board of Pain Medicine and can be reached at Florida Spine Institute and Wellness.
Dr. Torres was born in Spain and grew up in Puerto Rico. He graduated from the University of Puerto Rico School of Medicine. Dr. Torres performed his physical medicine and rehabilitation residency at the Veterans Administration Hospital in San Juan before completing a musculoskeletal fellowship at Louisiana State University Medical Center in New Orleans. He served three years as a clinical instructor of medicine and assistant professor at LSU before joining Florida Spine Institute in Clearwater, Florida, where he is the medical director of the Wellness Program.
Dr. Torres is an interventional physiatrist specializing in diagnosing and treating patients with spine-related pain syndromes. He is certified by the American Board of Physical Medicine and Rehabilitation and the American Board of Pain Medicine. He is a prolific writer and primarily interested in preventative medicine. He works with all of his patients to promote overall wellness.
